Skip to main content

Clinical Trials Using Relatlimab

Review the clinical trials studying relatlimab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 462 locations
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) versus Standard of Care (Lomustine) for the Treatment of Patients with Recurrent Glioblastoma
Status: Active
Location: 300 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 72 locations
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Status: Active
Location: 29 locations
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Status: Active
Location: 14 locations
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Status: Active
Location: 4 locations
Sarilumab in Combination with Ipilimumab, Nivolumab, and Relatlimab for the Treatment of Unresectable Stage IIIB/C/D or Stage IV Melanoma
Status: Active
Location: 4 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Status: Active
Location: 4 locations
Nivolumab, Relatlimab and Ipilimumab versus Nivolumab and Ipilimumab for the Treatment of Untreated Stage IV Renal Cell Cancer
Status: Active
Location: 3 locations
Nivolumab and Relatlimab in Treating Patients with Locally Advanced or Metastatic Mismatch Repair Deficient Solid Tumors Resistant to Prior PD-L1 Therapy
Status: Active
Location: 2 locations
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Nivolumab with or without Relatlimab given Prior to Surgery and Temozolomide and Radiation Therapy for the Treatment of IDH Wildtype Newly Diagnosed Glioblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Ipilimumab in Combination with Relatlimab and Nivolumab for the First Line Therapy in Patients with Stage III-IV Unresectable or Metastatic Melanoma, TRINITY Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intralesional Influenza Vaccine for the Treatment of Stage I-III and IV Melanoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Memory-Like Natural Killer Cell Therapy with Interlekin-2, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced or Metastatic Melanoma after Progression on Checkpoint Inhibitors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri